Back
ESC Premium Access

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

Session: Congress committee e-posters choice in pharmacology and pharmacotherapy
Topic: Lipid-Lowering Agents
Speaker: Doctor Q. Ying (Ningbo, CN)
Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor Qidi Ying

Ningbo NO2 Hospital, Ningbo (China)
0 follower

17 more presentations in this session

Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants

Speaker: Mr A. Holt (Copenhagen, DK)

Access
Abstract
Slides
Thumbnail

Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates

Speaker: Mr A. Holt (Copenhagen, DK)

Access
Abstract
Slides
Thumbnail

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

Speaker: Doctor M. Delbeck (Wuppertal, DE)

Access
Abstract
Slides
Thumbnail

Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial

Speaker: Assistant Professor H. Fukaya (Sagamihara, JP)

Access
Abstract
Slides
Thumbnail

Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom

Speaker: Doctor Y. Lenz (Berlin, DE)

Access
Abstract
Slides
Thumbnail

Access the full session

Congress committee e-posters choice in pharmacology and pharmacotherapy

Speakers: Doctor Q. Ying, Mr A. Holt, Mr A. Holt, Doctor M. Delbeck, Assistant Professor H. Fukaya...
Access
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb